David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Jul

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Peter Clark, MA, MD, FRCP: A Payer Perspective

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

Long-Term Follow-up of Postoperative Chemoradiotherapy With 3-Weekly vs Weekly Cisplatin in Head and Neck Cancer

Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity

Advanced Gastric or GEJ Cancer First-Line Disitamab Vedotin, Tislelizumab, and S-1

In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types